Stro Pipe - Search News

Sutro Biopharma rises after market hours on portfolio review, restructuring

Sutro Biopharma (NASDAQ:STRO) said on Thursday that, under its portfolio review, the company has decided to advance its dual-payload ADC programs, while deprioritizing development of luveltamab ...

MarketWatch · 3d

Sutro Biopharma Review Results in 50% Workforce Reduction, CEO Transition

Sutro Biopharma will cut its workforce by half after completing a strategic review of the company's portfolio. Its top executive will also step down, as it switches focus to its next-generation pipeline of cancer treatments,

Business Insider · 3d

Sutro Biopharma announces CEO Bill Newell to step down, 50% headcount reduction

Sutro Biopharma (STRO) announced the completion of a strategic portfolio review resulting in the prioritization of its three wholly-owned

Yahoo Finance3d

Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates

Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to earnings of $0.42 per share a year ago.

Business Insider3d

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sutro Biopharma (STRO) and Generation Bio (GBIO)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sutro Biopharma (STRO – Research Report) and Generation Bio (GBIO – Research Report).

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Trending now